On October 20th, Redwood Pharma AB (publ.) will present at the French-Swedish Life Science Day organized by Business Sweden, the Swedish Embassy and strategic partners at the Swedish Embassy in Paris.
The conference will gather early stage and highly innovative medical technology and biotechnology companies from Sweden and France. European life science investors as well as executives from pharmaceutical companies will participate. With a partnering and investment focus, the goal of the conference is to create an arena for participants to establish new contacts and to identify business opportunities. Redwood has been given the opportunity to present at this forum and to continue building its international network.
”France is one of Europe’s leading nations within the Life Science community – with a robust blend of domestic and multinational pharmaceutical firms that are actively seeking business partnerships, as well as venture capital and other investors interested in building new companies. Redwood Pharma is grateful for the invitation to represent the Swedish delegation and present our company and innovative technologies within ophthalmology and drug delivery to those stakeholders in attendance. Partnerships are vital to our future success,” says CEO Martin Vidaeus.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
French-Swedish Life Science Day 2016: www.b2match.eu/lifescienceday2016
Swedish Embassy, 17 Rue Barbet de Jouy, Paris, France
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com